Published in J Hypertens on July 01, 2008
Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther (2010) 1.66
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int (2012) 1.60
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes (2015) 1.33
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev (2012) 1.01
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch (2008) 0.92
Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies. Curr Hypertens Rep (2011) 0.87
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism (2013) 0.82
Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy. PLoS One (2014) 0.75
Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart. J Hypertens (2008) 0.75
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 3.03
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006) 2.79
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med (2011) 2.68
Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med (2005) 2.59
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem (2007) 2.44
Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg (2012) 2.39
One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res (2007) 2.36
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med (2008) 2.25
Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol (2008) 2.24
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol (2008) 1.99
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (2007) 1.93
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet (2002) 1.89
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int (2005) 1.78
Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem (2010) 1.77
Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. Nephrol Dial Transplant (2009) 1.76
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation (2012) 1.75
Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (2010) 1.74
Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension (2002) 1.73
Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem (2002) 1.72
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem (2010) 1.65
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res (2012) 1.61
IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3- cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A (2006) 1.61
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol (2003) 1.60
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant (2008) 1.56
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension (2006) 1.55
Isolation and potential existence of side population cells in adult human kidney. Int J Urol (2008) 1.55
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol (2014) 1.55
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab (2004) 1.54
Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun (2002) 1.53
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol (2004) 1.52
Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. Circ J (2009) 1.52
Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int (2008) 1.52
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res (2009) 1.52
Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol (2006) 1.51
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (2009) 1.47
Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res (2003) 1.46
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res (2002) 1.44
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol (2010) 1.43
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension (2007) 1.43
Restraint stress induces connexin-43 translocation via α-adrenoceptors in rat heart. Circ J (2010) 1.43
Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy--prospective multicenter cohort study. Int J Cardiol (2013) 1.40
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension (2003) 1.40
Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells (2006) 1.38
Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest (2005) 1.38
Lung injury following acute kidney injury: kidney-lung crosstalk. Clin Exp Nephrol (2011) 1.38
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res (2003) 1.38
Wrong primer for rat angiotensinogen mRNA. Am J Physiol Renal Physiol (2005) 1.38
Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res (2007) 1.37
Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol (2006) 1.37
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int (2002) 1.37
Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab (2005) 1.36
Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int (2004) 1.36
Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest (2011) 1.35
Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol (2007) 1.35
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension (2002) 1.34
Central control of bone remodeling by neuromedin U. Nat Med (2007) 1.32
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab (2007) 1.31
Musculin/MyoR is expressed in kidney side population cells and can regulate their function. J Cell Biol (2005) 1.31
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci (2004) 1.31